Table 2. Overall description of comorbidities, medication usage and general complications.
| Variables | non-AKI group | CoV-AKI group | p Value |
|---|---|---|---|
| (n = 80) | (n = 198) | ||
| Hospitalization ICU (%) | 30 (37.5%) | 138 (69.7%) | <0.001* |
| Comorbidities (%) | |||
| Hypertension | |||
| No | 46.1 | 29.5 | 0.010* |
| Yes | 53.9 | 70.5 | |
| Type 2 Diabetes | |||
| No | 67.1 | 58.4 | 0.190 |
| Yes | 32.9 | 41.6 | |
| Smoking | |||
| No | 76.3 | 66.8 | 0.129 |
| Yes | 23.7 | 33.2 | |
| Obesity | |||
| No | 85.5 | 83.2 | 0.635 |
| Yes | 14.5 | 16.8 | |
| Chronic Respiratory Disease | |||
| No | 85.5 | 83.7 | 0.758 |
| Yes | 14.5 | 16.3 | |
| Cardiopathy | |||
| No | 81.6 | 77.9 | 0.506 |
| Yes | 18.4 | 22.1 | |
| Hepatic Diseases | |||
| No | 98.7 | 93.6 | 0.085 |
| Yes | 1.3 | 6.4 | |
| Previous AKI | |||
| No | 92.1 | 85.3 | 0.135 |
| Yes | 7.9 | 14.7 | |
| Medication Use (%) | |||
| Hydroxychloroquine | |||
| No | 93.8 | 98.0 | 0.071 |
| Yes | 6.2 | 2.0 | |
| Azithromycin | |||
| No | 73.8 | 78.3 | 0.416 |
| Yes | 26.2 | 21.7 | |
| Hydroxycloroquine+Azithromycin | |||
| No | 68.8 | 49.5 | 0.003* |
| Yes | 31.2 | 50.5 | |
| Vasopressor agents | |||
| No | 93.7 | 50.9 | <0.001* |
| Yes | 6.3 | 49.1 | |
| Complications (%) | |||
| Sepsis | |||
| No | 38.8 | 45.5 | 0.759 |
| Yes | 61.3 | 54.5 | |
| SOFA Score | |||
| 0–6 | 83.7 | 65.4 | |
| 7–9 | 8.2 | 18.7 | 0.123 |
| 10–12 | 8.2 | 9.3 | |
| 13–14 | 0 | 5.6 | |
| 15 | 0 | 0.9 | |
| 15–24 | 0 | 0 | |
| Mechanical Ventilation | |||
| No | 85.4 | 44.5 | < 0.001* |
| Yes | 14.6 | 55.5 |
Description of comorbidities, medication usage and general complications between COVID-19 AKI patients and COVID-19 non-AKI patients. SOFA: Sequential Organ Failure Assessment. Data were expressed as percentage and analyzed using Chi-Square test. (*p<0.05).